Idenix Pharmaceuticals,
Inc. IDIX, a biopharmaceutical company engaged in the discovery and
development of drugs for the treatment of human viral diseases, today
announced that it will present data on IDX719, the Company's pan-genotypic HCV
NS5A inhibitor, at the 48^th Annual Meeting of the European Association for
the Study of the Liver (EASL) which is being held April 24 – 28, 2013 in
Amsterdam, the Netherlands. Full abstracts can now be viewed at the EASL
website at www.easl.eu.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in